55488-81-8

Basic information

• Product Name: Methyl 5-bromo-4-chloro-2-hydroxybenzoate
• Synonyms: Benzoic acid, 5-bromo-4-chloro-2-hydroxy-, methyl ester
• CAS NO: 55488-81-8
• Molecular Formula: C₈H₆BrClO₃
• Molecular Weight: 265.49
• Product Categories: blocks;Bromides;Carboxes
• Mol File: 55488-81-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 296.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.725±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 8.24±0.23(Predicted)
• CAS DataBase Reference: Methyl 5-bromo-4-chloro-2-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-bromo-4-chloro-2-hydroxybenzoate(55488-81-8)
• EPA Substance Registry System: Methyl 5-bromo-4-chloro-2-hydroxybenzoate(55488-81-8)

Safety Data

• Hazardous Substances Data: 55488-81-8(Hazardous Substances Data)

Upstream product

• 5106-98-9 4-chlorosalicylic acid 
• 67-56-1 methanol 
• 142167-38-2 5-bromo-4-chloro-2-hydroxybenzoic acid 

Downstream Products

• 142167-38-2 5-bromo-4-chloro-2-hydroxybenzoic acid 
• 1026449-11-5 5-bromo-4-chloro-2-hydroxybenzamide 

Relevant articles and documents

Big catkin willow acids compounds and medical use

The invention discloses a AMPK agonist activity with salicylic acid compound and its preparation method and medical use, it is the structural formula of the formula (I) compound of formula, its pharmaceutically acceptable salt or prodrug or solvate. The structure of the invention of formula (I) compound of formula activated AMPK, therefore can be used for preparing the prevention or treatment of AMPK mediated diseases.

Structure activity relationship for derivatives of xipamide (4 chloro 5 sulfamoyl 2',6' salicyloxylidide)

The synthesis of various derivatives of 4 chlorosalicylic acid substituted in position 5 is described. The evaluation of their diuretic potency on the rat showed 4 chloro 5 sulfamoyl 2',6' salicyloxylidide (BE 1293, xipamide, 'Aquaphor') as the most effective. The normal urinary volume is increased 10 fold by an oral dose of 100 mg/kg body weight. All changes in the molecular structure of xipamide, even acetylation, the introduction of a second sulfamoyl group or the exchange of the sulfonic group for the carbonyl group lead to a decrease in activity.